RESUMO
Hepatocellular carcinoma (HCC) stands as a major health problem worldwide. The management of advanced HCC, limited for a longtime by the disappointing results of conventional cytotoxic chemotherapies, has recently changed with the publication of the results of the Sorafenib Hepatocellular Carcinoma Assessment Randomized Protocol (SHARP) trial, which demonstrated an overall survival benefit over placebo in patients with advanced HCC. This study was further confirmed by the Asian-Pacific trial using sorafenib in Eastern patients. Those trials demonstrated that therapeutic benefits may derive from improving our knowledge of deregulated signaling pathways involved in HCC carcinogenesis. This review summarizes the results of clinical trials in which targeted therapies are currently evaluated aiming to enlarge the therapeutic armamentarium for HCC in a near future.
Assuntos
Carcinoma Hepatocelular/tratamento farmacológico , Neoplasias Hepáticas/tratamento farmacológico , Inibidores da Angiogênese/uso terapêutico , Benzenossulfonatos/uso terapêutico , Quimioterapia Combinada , Fator de Crescimento Epidérmico/antagonistas & inibidores , Humanos , Indóis/uso terapêutico , Niacinamida/análogos & derivados , Compostos de Fenilureia , Inibidores de Proteínas Quinases/uso terapêutico , Piridinas/uso terapêutico , Pirróis/uso terapêutico , Sorafenibe , SunitinibeRESUMO
Because of its pronostic, occurrence of cancer leads patients to questioning about death, life, and illness. Medical and paramedical staffs are often confronted to such questions, which can embarrassed them because not enough prepared and educated about them. How to help patients spiritually ? How to face a situation ethically ? Young french oncologists expose us their own experience and different trains of thought.